Synairgen (LON:SNG) Trading Up 6.3% – Here’s Why

Synairgen plc (LON:SNG)’s share price was up 6.3% during trading on Friday . The company traded as high as GBX 2 ($0.02) and last traded at GBX 1.97 ($0.02). Approximately 910,053 shares were traded during trading, a decline of 62% from the average daily volume of 2,394,704 shares. The stock had previously closed at GBX 1.85 ($0.02).

Synairgen Price Performance

The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09. The firm has a market cap of £5.09 million, a P/E ratio of -84.33 and a beta of -2.23. The business has a fifty day moving average of GBX 3.41 and a 200 day moving average of GBX 3.88.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).